1. Home
  2. CBLL vs SEPN Comparison

CBLL vs SEPN Comparison

Compare CBLL & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBLL
  • SEPN
  • Stock Information
  • Founded
  • CBLL 2014
  • SEPN 2022
  • Country
  • CBLL United States
  • SEPN United States
  • Employees
  • CBLL N/A
  • SEPN N/A
  • Industry
  • CBLL
  • SEPN
  • Sector
  • CBLL
  • SEPN
  • Exchange
  • CBLL Nasdaq
  • SEPN NYSE
  • Market Cap
  • CBLL 767.6M
  • SEPN 631.0M
  • IPO Year
  • CBLL 2024
  • SEPN 2024
  • Fundamental
  • Price
  • CBLL $19.46
  • SEPN $6.10
  • Analyst Decision
  • CBLL Strong Buy
  • SEPN Buy
  • Analyst Count
  • CBLL 5
  • SEPN 4
  • Target Price
  • CBLL $33.25
  • SEPN $33.00
  • AVG Volume (30 Days)
  • CBLL 177.6K
  • SEPN 413.3K
  • Earning Date
  • CBLL 05-14-2025
  • SEPN 03-27-2025
  • Dividend Yield
  • CBLL N/A
  • SEPN N/A
  • EPS Growth
  • CBLL N/A
  • SEPN N/A
  • EPS
  • CBLL N/A
  • SEPN N/A
  • Revenue
  • CBLL $65,444,000.00
  • SEPN $1,075,000.00
  • Revenue This Year
  • CBLL $30.47
  • SEPN N/A
  • Revenue Next Year
  • CBLL $29.61
  • SEPN N/A
  • P/E Ratio
  • CBLL N/A
  • SEPN N/A
  • Revenue Growth
  • CBLL 44.71
  • SEPN 611.92
  • 52 Week Low
  • CBLL $18.69
  • SEPN $4.17
  • 52 Week High
  • CBLL $32.75
  • SEPN $28.99
  • Technical
  • Relative Strength Index (RSI)
  • CBLL N/A
  • SEPN N/A
  • Support Level
  • CBLL N/A
  • SEPN N/A
  • Resistance Level
  • CBLL N/A
  • SEPN N/A
  • Average True Range (ATR)
  • CBLL 0.00
  • SEPN 0.00
  • MACD
  • CBLL 0.00
  • SEPN 0.00
  • Stochastic Oscillator
  • CBLL 0.00
  • SEPN 0.00

About CBLL CeriBell Inc. Common Stock

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

Share on Social Networks: